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Abstract
Ferrets are a useful animal model for human influenza virus infections, since they closely mimic the pathogenesis of
influenza viruses observed in humans. However, a lack of reagents, especially for flow cytometry of immune cell subsets, has
limited research in this model. Here we use a panel of primarily species cross-reactive antibodies to identify ferret T cells,
cytotoxic T lymphocytes (CTL), B cells, and granulocytes in peripheral blood. Following infection with seasonal H3N2 or
H1N1pdm09 influenza viruses, these cell types showed rapid and dramatic changes in frequency, even though clinically the
infections were mild. The loss of B cells and CD4 and CD8 T cells, and the increase in neutrophils, were especially marked 1–
2 days after infection, when about 90% of CD8+ T cells disappeared from the peripheral blood. The different virus strains led
to different kinetics of leukocyte subset alterations. Vaccination with homologous vaccine reduced clinical symptoms
slightly, but led to a much more rapid return to normal leukocyte parameters. Assessment of clinical symptoms may
underestimate the effectiveness of influenza vaccine in restoring homeostasis.
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Influenza viruses are common human respiratory pathogens
that infect millions of people annually and cause an estimated 0.5
million deaths globally [1–4]. Seasonal human influenza viruses,
including H3N2 and the 2009 pandemic H1N1 (H1N1pdm09)
viruses, usually initiate infection in the upper respiratory tract.
Clinical symptoms including fever, dry cough, sneezing, myalgia,
and lethargy begin a few days after infection. In most cases, the
upper respiratory tract infections are then cleared and the
individual develops immunity to the specific strain of virus,
although antigenic variants (‘‘drifted’’ viruses) may escape this
immunity to infect the same person in subsequent years. The
disease caused by influenza infection is occasionally severe,
especially when the virus spreads to the lower respiratory tract.
As well, for reasons that are as yet unclear, influenza infection
predisposes patients to secondary infection with bacteria, such as
Streptococcus pneumoniae or S. pyogenes that rarely cause serious
infections alone, and this superinfection is linked to increased
disease severity [5–7].
A variety of animal models have been used to characterize the
host and its immune response to infection, disease course,
pathogenesis, and transmission of influenza viruses, as well as for
the development of diagnostics, therapeutics, and vaccines [8,9].
Commonly-used animal models include mice, guinea pigs, ferrets
and sometimes non-human primates (NHP). Each model has
advantages and disadvantages. Mice are easily housed and
handled, and a large repertoire of mouse-specific reagents and
transgenic and knock-out strains are available for analyzing host
responses to infection or immunization. However, mice are not
natural hosts for influenza virus, and human influenza viruses
usually require adaptation to efficiently replicate and cause disease
in mice [9–12], while these mouse-adapted strains may not
accurately recapitulate natural infection of humans. Guinea pigs
are useful models for the study of virus transmission, but show few
if any clinical symptoms of infection [13]. NHP may be the most
similar to humans in terms of immunological responses [14], but
are expensive and difficult to handle and house.
The ferret remains the most widely accepted small animal
model for influenza virus infection and vaccine protection studies
[15–18]. Ferrets are readily infected with human and avian
influenza viruses without the need for prior adaptation, and in
general the course of infection in ferrets recapitulates that seen in
susceptible humans. A major disadvantage to the ferret model of
influenza virus infection and immunity, however, is the paucity of
ferret-specific reagents available for analysis of the host response.
In particular, the ability to identify leukocyte subsets is limited,
making it difficult to characterize the immune response to
influenza virus infection.
Several groups have begun to identify and develop antibody
reagents that identify ferret leukocyte subsets [19–22]. We have
adapted and extended previous findings in order to track ferret
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peripheral blood leukocyte (PBL) subsets on a daily basis
following influenza virus infection. We find that, even though
clinical symptoms were mild, circulating leukocyte subsets
showed rapid, dynamic, and profound change in response to
infection. Vaccination against influenza significantly reduced the
virus-induced changes in PBL, despite only having modest
effects on clinical symptoms. As well as providing a more
detailed view of the inflammatory impact of influenza virus
infection, these observations may help explain the protective
effect of vaccination against secondary bacterial infection
following influenza virus infection.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with Animal
Welfare Act regulations by the United States Department of
Agriculture (USDA) and Public Health Service Policy on Humane
Care and Use of Laboratory Animals (PHS Policy) administered
by the National Institutes of Health (NIH). All animal research was
conducted under Centers for Disease Control and Prevention’s
Institutional Animal Care and Use Committee (IACUC) approved
protocol #2884YORFERC-A4: ‘‘Influenza Vaccine Development
and Evaluation’’ in an Association for Assessment and Accredi-
tation of Laboratory Animal Care (AAALAC) International-
accredited animal facility. Animal welfare was monitored on a
daily basis, and all animal handling was performed under light
anesthesia (described below) and all efforts were made to minimize
suffering. Humane endpoints for this study included the presen-
tation of body weight loss exceeding 20% (relative to weight at
challenge), indications of neurological symptoms, or a clinical
score of 3 in any category based on the system designed by
Reuman et al. [18]. However, none of the animals in this study
met those criteria.
Viruses and vaccines
Virus stocks for A/Perth/16/09 (H3N2) (Perth/16) and for A/
New York/21/2009 (H1N1pdm09) (NY/21) were propagated in
the allantoic cavity of 10 day-old fertile white embryonated
chicken eggs (Hy-line, Mansfield, GA) at 34uC for 48 h. Virus
containing allantoic fluid was harvested, aliquoted and frozen at 2
80uC until used in experiments. Stocks were titered in a standard
plaque assay and expressed as plaque forming units (pfu) [23]
using Madin-Darby Canine Kidney (MDCK) cells. The commer-
cial 2011–2012 Fluarix trivalent inactivated influenza vaccine
(TIV) (GlaxoSmithKline Biologicals, Research Triangle Park, NC)
was used. This vaccine included HA and NA from A/California/
07/2009 (H1N1pdm), A/Victoria/210/2009 (H3N2) and B/
Brisbane/60/2008 viruses. A/Victoria/210/2009 (H3N2) virus is
antigenically similar to Perth/16 virus, and A/California/07/2009
virus is antigenically similar to NY/21 virus [24]. Appropriate
control antigens for serological testing were obtained from the
Influenza Reagent Resource (IRR: Influenza Division, WHO
Collaborating Center for Surveillance, Epidemiology and Control
of Influenza, Centers for Disease Control and Prevention, Atlanta,
GA).
Ferrets, blood samples, nasal washes, and viral challenge
Male Fitch ferrets, approximately 6 months of age (Triple F
Farms, Sayre, PA), serologically negative by hemagglutination
inhibition (HI) assay for currently circulating human influenza H1,
H3 and type B viruses, were used in this study. Prior to the
initiation of the studies, all ferrets were evaluated by a licensed
veterinarian and determined to be in good health and free from
malformations and signs of clinical disease. During the 14 day
quarantine period, animals were randomized by weight into
groups. Ferrets were maintained in standard housing, provided
with commercial food pellets and water, and were pair -housed
during the quarantine period and after infection. Excreta pans
under the cages, cage flooring, and room floors were cleaned daily.
For vaccination, ferrets were injected intramuscularly (IM) with
an adult human dose (0.5 ml or 15 mg of HA) per ferret, followed
by a booster vaccination 21 days later. Control ferrets were mock
vaccinated with phosphate-buffered saline (PBS).
Groups of 4 ferrets (body weight: 1–1.3 kg) were infected
intranasally with 16106 PFU of H1N1pdm09 (NY/21) or H3N2
(Perth/16), diluted in 0.5 ml of sterile PBS, or were mock infected
with 0.5 ml of sterile egg allantoic fluid, diluted 32 ml/468 ml in
PBS (to be equal to the amount of stock virus used for infection per
ferret), intranasally. In the case of Perth/16, as well as naı̈ve
animals, vaccinated ferrets were infected 35 days after the initial
vaccination (14 days post-boost). Baseline weights and tempera-
tures were obtained for the three consecutive days prior to
challenge and on day 0 (the day of challenge). Body temperatures
were measured using an implantable subcutaneous temperature
transponder (BioMedic Data Systems, Inc., Seaford, DE).
Following challenge, ferrets were monitored for changes in body
weight and temperature as well as clinical signs of illness (sneezing,
lethargy, nasal discharge, diarrhea and neurological dysfunction)
on a daily basis for two weeks. Animals were anesthetized with a
cocktail of 22 mg ketamine and 2 mg xylazine per kg of body
weight, respectively, and blood samples of 200–250 ml taken from
the cranial vena cava [25] on days 0, 1, 2, 3, 4, 5, 6, 7, 9, 11, and
13 relative to the day of challenge. Blood samples were collected
from alternate sides each day, and care was taken to avoid
hematoma formation. Nasal washes were collected with 1 ml of
PBS on days 1, 2, 3, 4, 5, 6, 7, 9, and 11. Titers were determined
by standard plaque assay on MDCK cells from challenge with
Perth/16 or NY/21 virus.
All ferrets were euthanized on day 14 post-challenge. Animals
were sedated prior to intracardiac administration of an overdose of
euthanasia agent containing pentobarbital. Discomfort and
distress were limited to that which was unavoidable in the
conductance of the study.
Serology
To assess antibody responses, serum was collected prior to
vaccination, 21 days post-vaccination (i.e. the day of the second
vaccination), on the day of viral challenge (i.e. 14 days after the
second vaccine dose), and 7 and 14 days post-challenge. HI assays
were performed as previously described [26]. Sera were treated
with Vibrio cholerae neuraminidase, also known as receptor-
destroying enzyme (RDE) (Denka Seiken Co. Ltd., Tokyo, Japan)
and diluted to a starting dilution of 1:10 with PBS, pH 7.2. RDE
treated serum samples (25 ml) were incubated with equal volumes
of inactivated viruses (4 hemagglutinating units [HAU] of A/
California/07/2009 (H1N1pdm), A/Perth/16/2009, A/Victoria/
210/2009 (H3N2) and B/Brisbane/60/2008 (IRR) at room
temperature (RT) for 30 minutes. Then, an equal volume of
0.5% turkey red blood cells (Lampire Biological Laboratories,
Pipersville, PA) was added and incubated at RT for 30 minutes.
HI assays were performed in Nunc V-bottomed 96-well microtiter
plates (Thermo Fisher Scientific, Rochester, NY). The HI titer was
expressed as the reciprocal of the highest dilution of the samples
inhibiting hemagglutination.
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Antibodies
The antibodies used for flow cytometry, providing recognition
of CD3, CD8, CD11b, and CD79a, are summarized in Table 1.
While these experiments were in progress, an antibody against
ferret CD4 became available and was also used in the experiments
involving infection of naı̈ve animals with Perth/16 and NY/21.
Otherwise, as indicated in chart titles, CD4 cell frequency was
estimated as CD3+/CD82 cells, which are almost all CD4+
(Figure 1).
Preparation of leukocytes
Complete blood counts were quantified from whole blood
collected in EDTA Vacutainer tubes (Tyco HealthCare Group
LP, Mansfield, MA) using a Hemavet HV950FS instrument per
the manufacturer’s instructions (Drew Scientific, Inc., Oxford,
CT). PBL were purified by hypotonic lysis of red blood cells (RBC)
using erythrocyte lysing solution (0.15 M NH4Cl, 10 mM
KHCO3, and 1 mM EDTA pH 7.3). One volume of fresh venous
blood collected in a tube containing EDTA as anticoagulant was
Figure 1. Flow cytometry of ferret peripheral blood leukocytes. Representative stains for (A) unstained, unpermeablized cells after gating
out doublets; (B) CD3 vs CD79a; (C) CD11b; (D) CD3 vs CD11b; (E) CD3 vs CD4; (F) CD3 vs CD8; (G) CD4 vs CD8 (ungated cells); (H) CD4 vs CD8 (CD3
gated cells); (I) CD3 vs CD8 vs CD79a (B cells: Green; CD8+ve T cells: Red; CD8-ve T cells: Blue; Granulocytes/NK cells/Monocytes/DC: Gray); (J) FSC vs
SSC vs CD11b (Monocytes/DC: Red; Lymphocytes: Blue; Granulocytes: Gray).
doi:10.1371/journal.pone.0100926.g001
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mixed with 69 volumes of erythrocyte lysis solution and shaken for
6 minutes at room temperature. After RBC lysis, PBL were
pelleted for 10 minutes at 3156g, 4uC. The cell pellet was washed
twice with flow buffer [HBSS-5+ EDTA solution (HBSS without
Ca2+/Mg2+; 5% fetal bovine serum (HyClone, South Logan, UT),
HEPES 10 mM, and EDTA 10 mM)], and PBL were counted,
and adjusted to 26106 cells/ml in flow buffer.
Cells were labeled with surface Abs (anti-CD8, anti-CD11b and
in some experiments anti-MHC class II and anti-CD4) then fixed
and permeabilized using a Cytofix/Cytoperm Plus Fixation/
Permeabilization Kit (BD, San Jose, CA) for intracellular staining
(anti-CD3 and anti-CD79a). Isotype controls (eBioscience, San
Diego, CA) were included for all antibodies. Data were acquired
on a FACSCanto II flow cytometry apparatus (BD), and analyzed
using FlowJo software (Tree Star, Ashland, OR).
Statistical analysis
Statistical significance and 95% confidence intervals were
calculated using a linear mixed model with repeated measures,
implemented in the SAS program. Compound symmetry was used
for the covariance structure for flow cytometry values; unstruc-
tured covariance was used for the HI titers. Confidence intervals
were calculated using compound symmetry covariance to pool
variability between groups. A p value ,0.05 was used as the cutoff
for statistical significance.
Results
Antibodies and flow cytometry
We confirmed previous results [19,21,22] that several antibodies
produced against cell surface markers of other mammalian species
cross-reacted with ferret CD3, CD8, and CD11b. In addition, we
identified an antibody against human CD79a that cross-reacted
with ferret CD79a (summarized in Table 1). In combination with
forward and side scatter (FSC and SSC, respectively), these
antibodies allowed us to identify B cells (CD79a+), T cells (CD3+),
CD8 T cells (CD3+ and CD8+), granulocytes (predominately
neutrophils) (CD11b moderate SSC high FSC high), and
monocytes (CD11b high SSC moderate FSC high) (Figure 1). In
some experiments, we also used anti-ferret CD4 (Table 1) to
identify TH cells (CD3+ and CD4+) (Figure 1). In our hands, some
other antibodies (such as CD25 (7D4), CD79b (CB3-1), IFN
gamma (XMG1.1) and TNF alpha (MP6-XT22), previously
suggested to be cross-reactive with ferret antigens, appeared to
be either poorly reactive or non-specific (data not shown).
These results confirm and extend previous findings [19,21,22],
allowing us to more comprehensively track PBL subsets in the
ferret challenge model.
Normal values, based on 20–40 uninfected ferrets, are shown in
Table 2 and are consistent with previous values (estimated based
on cell morphology in blood smears) for neutrophils, lymphocytes,
and monocytes in this species [27]. As expected for these outbred
animals, there was considerable inter-animal variability in
leukocyte counts (standard deviation , 25–45% of average);
however, for a given animal, most leukocyte counts were relatively
stable over the duration of the experiments (14–49 days; standard
deviation for individual animals , 10–15% of average; data not
shown). The exceptions were the monocyte/dendritic cell subset
(SD ,30% of average for individual animals), and CD79a+ cells
(B cells) (SD , 25% of average). Since we do not as yet have
reagents that specifically identify ferret monocytes/dendritic cells,
they were defined as CD11b-high/FSC-high, and are fairly small
subpopulations that are relatively difficult to separate from
granulocytes (CD11b+/FSC-moderate-high) (Figure 1C). The
reason for the volatility of B cell counts is not known. In several
cases, individual uninfected animals showed 2-fold or greater
changes in B cell frequency over 1 or 2 days. To account for the
inter-animal variability, in the experiments shown here we
normalize each subset to the value observed for that individual
on day 0 (i.e. immediately before infection). However, the patterns
observed were very similar even without normalization (Figure
S1).
Serological responses
All ferrets were seronegative for influenza viruses before
vaccination, and unvaccinated animals remained seronegative.
Vaccinated animals developed modest HI titers against the three
components of the vaccine (Figure 2A, B, C). Three of four
vaccinated animals developed HI titers $40 against Perth/16 by
the day of challenge (day 35 post-immunization), while the fourth
animal developed a titer of 20. These titers are similar to those
previously described for ferrets immunized with TIV [28]. HI
titers of 40 or more are generally used as an immune correlate of
protection against influenza among humans [29–31].
Following viral challenge, HI antibody titers to the challenge
virus increased by day 7–9 post-infection and by day 14 post-
challenge, GMTs had increased by greater than 150-fold over pre-
challenge titers (p,0.001) (Figure 2A, D, E). This response was
specific to the challenge virus, since no corresponding increase in
titer was seen to the heterologous viruses (Figure 2B, C, F).
Vaccinated animals showed a more rapid increase in antibody titer
than naı̈ve animals, with a significantly higher GMT at day 7 post-
challenge (p = 0.024), but by 14 days post-challenge naı̈ve and
vaccinated animals had similar titers (p = 0.999) (Figure 2A).
Mock-infected ferrets did not seroconvert to influenza virus.
Clinical signs after viral challenge
Ferrets were challenged intranasally with 16106 PFU of Perth/
16 virus (H3N2), or with 16106 PFU of NY/21 virus
Table 1. Antibodies used in this study.
Species/Target Clone ID Company Fluor
Human CD3 PC3/188A Santa Cruz Biotechnology, Santa Cruz, CA FITC, AlexaFluor 647
Human CD8 OKT8 eBioscience, San Diego, CA eFluor 450
Ferret CD4 02 Sino Biological Inc., Beijing, China PE
Mouse CD11b M1/70 eBioscience, San Diego, CA FITC
Human CD79a HM47 eBioscience, San Diego, CA PerCP-Cy5.5
Bovine MHC class II CAT82A VMRD, Pullman, WA Unconjugated
doi:10.1371/journal.pone.0100926.t001
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(H1N1pdm09), or mock infected with the same dilution of sterile
allantoic fluid in sterile PBS. Mock-infected animals did not show
clinical signs, while infected ferrets all showed mild clinical signs,
whether they were vaccinated or naive (Figure 3).
H3N2-infected ferrets lost between 2.2% and 8% of their body
weight, with most animals beginning to regain weight after day 7
(Figure 3A, D). Vaccinated animals (range 2.2% to 5%) showed a
trend towards slightly less weight loss and more rapid recovery
compared to naı̈ve ferrets (range 3.3% to 8%), but this did not
reach statistical significance. Fever was observed on day 2, and on
several subsequent days (Figure 3B, E). Although vaccinated and
naı̈ve animals showed similar levels of fever on most of these days,
vaccinated ferrets had slightly lower body temperatures than naı̈ve
animals on days 1 and 5 (p,0.05) (Figure 3B).
Animals challenged with H1N1pdm09 showed similar, though
slightly more severe, symptoms than those challenged with Perth/
16 (Figure 3D–E). The mean maximum weight loss was 7.4% for
animals infected with H1N1pdm09 and 6.3% for animals infected
by H3N2, with H1N1pdm09-infected animals showing signifi-
cantly greater weight loss than H3N2-infected ferrets on days 2
and 4. Body weights started to recover after day 7 post-challenge,
but did not reach the pre-challenge (day 0) level by the end of this
study (Figure 3D). H1N1pdm09-infected animals also became
feverish earlier than did H3N2-infected ferrets (day 1 vs. day 2:
p = 0.0072 on day 1), while on subsequent days, temperatures
were similar in the groups (Figure 3E).
Virus shedding
Virus was recovered from nasal washes after infection
(Figure 3C, F). Virus shedding was observed at day 1 post-
challenge for all animals and was cleared by day 7 or 9 (Figure 3C,
F). Virus titers in H1N1pdm09-infected animals were higher than
in H3N2-infected, although the difference was significant only on
day 1 (p = 0.044) (Figure 3F). Vaccinated and naı̈ve H3N2-
infected ferrets shed similar titers of virus on the first 4 days post-
infection, but vaccinated animals shed significantly lower titers by
days 5 and 6 (Figure 3C). These results are similar to those
previously described for ferrets infected with H1N1pdm09 and
seasonal viruses [32–34]. Although the clinical protection
conferred by TIV was modest, it is similar to that previously
described for ferrets vaccinated with TIV [35].
In summary, H3N2 challenged animals exhibited only mild and
temporary clinical symptoms and H1N1pdm09 challenged
animals exhibited similar, but slightly more severe symptoms.
Vaccination with TIV led to a moderate serological response, and
a slight reduction in clinical signs and in virus shedding.
Leukocyte subsets in vaccinated and naı̈ve animals after
H3N2 challenge
Total peripheral leukocyte counts remained approximately
constant over the post-challenge period for all groups of ferrets,
although vaccinated animals showed a small increase in total
WBC counts on days 3 and 6 after infection (Figure 4A). Two days
after infection, when ferrets showed peak fever, CD3+ cell counts
decreased dramatically, to about 25% of pre-challenge or mock-
infected levels (p,0.001) (Figure 4B). Both CD8+ (Figure 4C) and
CD8- (mainly CD4+) (Figure 4D) T cells were affected, although
CD8+ T cells were consistently affected more than CD8-, with
some animals showing a disappearance of 90–95% of their CD8 T
cells on day 2.
In both naı̈ve and vaccinated ferrets, lymphocyte numbers
rebounded significantly on the 3rd day post-infection. By day 4, for
the vaccinated ferrets, CD3+, CD8+, and CD3+ CD82 cells
returned essentially to baseline (day 0) levels, while in naı̈ve ferrets
these cell types reached about 60% of normal levels, followed by a
second drop in cell counts on days 5 and 6 (Figure 4B–D) before
returning to normal levels on day 7. In vaccinated ferrets, CD3
and CD3+ CD82 counts were significantly greater than mock-
infected levels (Figure 4B, D), and were significantly greater than
baseline levels, from day 9 onward (Figure 4B–D). It is worth
noting that this biphasic pattern of inflammation, as seen in
temperature response (Figure 3B, E), has long been observed in
ferrets infected with influenza [36].
B cell (CD79a+) numbers also showed a marked drop 2 days
after infection, to 50–70% of mock-infected levels (Figure 4E).
However, B cell numbers in mock-infected animals also dropped
on day 4 and showed significant variability on several other days
post-challenge.
In contrast to the lymphocyte populations, granulocyte
(CD11b+; presumably predominately neutrophils) numbers in-
creased post-infection, with a peak on day 2 post-infection in both
vaccinated and naı̈ve animals (Figure 4F). For vaccinated animals,
CD11b+ counts returned essentially to normal levels after day 2,
whereas for naı̈ve animals, after a partial recovery on day 3, there
was a second peak in CD11b+ cell counts on days 4 and 5, with
numbers returning to normal from day 7 on. This granulocytosis
was not simply a relative increase due to the loss of lymphocytes,
but was an absolute increase in the numbers of cells (Figure S1F).
The monocyte/dendritic cell lineage also showed rapid and
marked changes, although relatively large fluctuations were also
seen in the mock-infected group of ferrets (Figure S1E). A transient
early increase in the cells on days 1–2 was followed by a return to
normal levels on day 3, followed by a second increase on days 5–6.
However, these changes were not statistically significant when
normalized to day 0 (data not shown).
The changes in lymphocytes and granulocytes during the first
three days post-infection were not only rapid and marked, these
Table 2. Normal cell values.
CD3+ve CD8+ve CD4+ve CD79a+ve CD11b+ve CD11b++
Average 29.3 5.6 17.0 13.4 37.0 3.9
(95% CI) (27.1–31.5) (4.8–6.4) (15.2–18.8) (11.9–14.9) (32.8–41.1) (3.4–4.3)
Range 15.3–45.2 1.9–13.7 9.5–23.4 4.6–24.5 12.9–63.3 1.7–7.9
StDev 7.1 2.5 4.1 4.7 13.4 1.5
Frequency of leukocyte subsets from 40 uninfected ferrets (except for CD4, for which 20 uninfected ferrets were used). Shown are the average value, the upper and
lower bounds of the 95% confidence intervals, the range (lowest and highest values observed), and the standard deviation.
doi:10.1371/journal.pone.0100926.t002
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changes were very consistent among animals, with each ferret
showing very similar duration and extent of change in cellularity
(Figure S2). Following these highly consistent changes in early
infection, lymphocyte and granulocyte numbers showed more
variation between individuals on subsequent days, though clear
trends were readily detected (Figure S2).
In summary, although clinical signs were relatively mild and
transient, changes in leukocyte subsets were rapid and dramatic.
Transient lymphopenia affected both CD8+ and CD3+/CD82 T
Figure 2. Hemagglutination inhibition (HI) titers. (A–C) Ferrets were immunized with commercial human TIV on days 0 and 21, and challenged
with Perth/16 on day 35. Blood samples were collected on days 0, 21, 35, 42, and 49. (D–F) Ferrets were challenged with Perth/16 and NY/21 on day
0. Blood samples were collected on days 0, 9 and 14. HI assays were performed using (A, D) A/Victoria/210/2009 (H3N2), (B, E) A/California/07/2009
(H1N1pdm), and (C, F) B/Brisbane/60/2008 antigen controls. ‘‘Mock’’, unvaccinated mock-infected animals; ‘‘Naı̈ve’’, unvaccinated animals challenged
with Perth/16; ‘‘TIV’’, vaccinated animals challenged with Perth/16; ‘‘H3N2’’, unvaccinated animals challenged with Perth/16; ‘‘H1N1pdm’’,
unvaccinated animals challenged with NY/21. { indicates p,0.0001; * indicates 0.0001,p,0.05. Error bars represent 95% confidence intervals,
calculated using compound symmetry covariance to pool variability across groups.
doi:10.1371/journal.pone.0100926.g002
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Figure 3. Clinical responses to infection. (A–C) Two weeks after booster vaccination, ferrets were challenged intranasally with 106 PFU of Perth/
16. (D–F) Unvaccinated ferrets were challenged intranasally with 16106 PFU of NY/21 or Perth/16. (A, D) Body weight and (B, E) temperature were
measured daily. Data shown are normalized to the individual animals’ weight or temperature on the day of challenge (day 0). (C, F) Nasal washes
were obtained on days 0–9 and virus titers in the nasal washes were measured. Error bars represent 95% confidence intervals. ‘‘Mock’’, unvaccinated
mock-infected animals; ‘‘Naı̈ve’’, unvaccinated animals challenged with Perth/16; ‘‘TIV’’, vaccinated animals challenged with Perth/16. ‘‘H3N2’’,
unvaccinated animals challenged with Perth/16; ‘‘H1N1pdm’’, unvaccinated animals challenged with NY/21. { indicates p,0.0001; * indicates
0.0001,p,0.05. ‘‘MvN’’, comparing mock-infected ferrets to naı̈ve ferrets; ‘‘MvT’’, comparing mock-infected ferrets to ferrets vaccinated with TIV;
‘‘NvT’’, comparing naı̈ve ferrets to ferrets vaccinated with TIV; ‘‘MvH3’’, comparing mock-infected ferrets to ferrets infected with H3N2; ‘‘MvH1’’,
comparing mock-infected ferrets to ferrets infected with H1N1pdm09; ‘‘H1vH3’’, comparing H1N1pdm09 infected ferrets to ferrets infected with
H3N2.
doi:10.1371/journal.pone.0100926.g003
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Figure 4. Peripheral blood leukocyte subsets following infection of vaccinated and naı̈ve animals with Perth/16. Ferrets were bled on
days 0–7, 9, 11, and 13 relative to the day of viral challenge, and cells were stained and analyzed by flow cytometry as described in the text. (A) Total
white blood cell counts were obtained using a Hemavet apparatus. Percentages of (B) CD3-positive cells (T cells), (C) CD8-positive cells (cytotoxic T
lymphocytes), (D) CD3-positive cells (T cells) and CD8-negative cells, (E) CD79a-positive cells (B cells), and (F) CD11b-positive cells excluding CD11b-
high/FSC-high cells (granulocytes) were measured. For each animal the frequencies were normalized to the ferret’s values on day 0; the Y axis
represents percent of values on day 0. ‘‘Mock’’, unvaccinated mock-infected animals; ‘‘Naı̈ve’’, unvaccinated animals challenged with Perth/16; ‘‘TIV’’,
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cells, with CD8+ T cells being more affected. Vaccinated animals
exhibited less marked changes in most subsets, and their leukocyte
subsets showed a faster return to normal levels than for
unvaccinated ferrets.
Leukocyte subsets in naı̈ve animals after H3N2 and
H1N1pdm09 challenge
We compared the effects of H1N1pdm09 infection on PBL
subsets to that of H3N2. Total WBC counts remained approx-
imately constant over the post-challenge period for all three groups
of ferrets, although H1N1pdm09-infected animals showed a
significant increase in total WBC counts on days 7 and 9 after
infection (Figure 5A). H3N2-infected animals showed very similar
responses in this experiment as in the previous experiment
(Figure 4). CD3+ T cells as well as CD8+ and CD4+ cells
dropped markedly on day 2 post-infection, with the reduction
being most dramatic for CD8+ cells. These cell types recovered
partially on days 3 and 4, followed by a second reduction on days 5
and 6, after which the cells returned to similar levels as mock-
infected (Figure 5B–D). B cells showed a similar though less
marked pattern, although again even mock-infected animals
showed significant variability (Figure 5E). CD11b+ granulocytes
increased significantly on day 2 post-infection, returned to
approximately base-line levels, and were again significantly higher
than mock-infected levels on day 6 (Figure 5F).
As with clinical symptoms, PBL subset changes in H1N1pdm09-
infected animals were similar to those in H3N2-infected, but
generally more marked. In particular, while H3N2-infected
animals showed little change until day 2 post-infection,
H1N1pdm09-infected animals showed significant changes in all
subsets examined on the first day after challenge. Whereas H3N2-
infected animals showed a very abrupt drop in T cell counts
followed by rapid, if partial, recovery, the H1N1pdm09-infected
ferrets had a longer trough and a less complete recovery for several
days. Interestingly, CD8+ cells, as in H3N2-infected animals,
showed a second drop on day 5, though to a lesser extent than in
H3N2-infected ferrets. Similarly, in H1N1pdm09-infected ani-
mals, granulocyte counts peaked on day 2 post-infection, but
remained elevated until day 6. Nevertheless, most PBL subsets
returned to approximately normal levels by about day 7 post-
infection (Figure 5).
Thus the changes within all subsets in H1N1pdm09-infected
animals were similar to those in H3N2-infected, but generally
more marked, and H1N1pdm09-infected animals showed signif-
icant changes in all subsets examined on the first day after
challenge.
Discussion
Ferrets are considered the most appropriate model animal for
the study of human influenza disease and immunity, because they
can be infected directly with human virus isolates and generally
show similar clinical signs and disease severity to humans infected
with the similar viruses [15–18]. Ferrets are large enough that
serial blood samples of ,250 ml, sufficient to perform flow
cytometric analysis, can be taken daily without depleting blood
volume or cellularity. Thus the ferret offers a relevant animal
model where the precise infectious dose, time post-infection, and
exposure history to influenza can be controlled. However, unlike
humans or mice, few ferret-reactive antibodies have been available
to identify specific leukocyte subsets in this species. Here, we used
a panel of species cross-reactive antibodies to measure the effect of
influenza virus infection on ferret leukocyte subsets. We found that
infection with human influenza viruses that induce only mild and
temporary clinical signs resulted in dramatic and rapid alterations
in leukocyte counts and ratios. These changes are similar to, but
generally more dramatic than, those described in human infections
with influenza viruses. This may reflect the relatively high dose of
virus used to infect ferrets, but it is also possible that the extent of
these early, transient changes in leukocytes may be underestimated
in human studies because of differences in timing of presentation
relative to infection. The limited number of studies in mice (which
are difficult because daily bleeds are not possible in this species,
meaning that groups of animals must be sacrificed on each day)
also indicate marked leukopenia following influenza virus infection
[37].
Mock-infected ferrets were treated and handled the same as
infected ferrets including a mock challenge containing the same
concentration of allantoic fluid as challenged animals, yet showed
little change in most cell parameters (total WBC, RBC, CD3+,
CD8+, CD11b+) over the 2-week course of the experiment. This
showed that the daily handling, sedation and blood samples alone
did not perturb the majority of the parameters we assessed.
However, even in mock-infected animals, B cells (CD79a+) did
show substantial fluctuations from day to day (e.g. from day 3 to 4,
Figure 4E; similar fluctuations were seen in all experiments). It is
not known whether ferret B cells are intrinsically more volatile
than T cells, or whether the handling and sedation involved in
blood collection, etc. (although ketamine/xylazine sedation is not
to our knowledge associated with changes in blood subsets), caused
these changes in B cells alone. In spite of the difficulty in
establishing a baseline value, ferrets did show changes in B cell
counts compared to mock-infected animals on several days
(Figures 4E, 5E); however, because of the variability in these cell
counts we place less emphasis on these changes than on those of
more consistent leukocyte subpopulations. Nevertheless, the
apparent volatility of B cell populations during the course of the
experiment warrants further study.
As previously reported, [32–34,38,39], infection with
16106 PFU of the seasonal viruses Perth/16 (H3N2) or NY/21
(H1N1pdm09) causes a mild and short-lived disease in ferrets.
Clinical signs included a brief and moderate rise in temperature
and ,10% weight loss (Figure 3A, B), with H1N1pdm09 causing a
slightly more severe disease than H3N2 at this challenge dose.
Nevertheless, peripheral blood leukocyte subsets showed substan-
tial and rapid changes, with marked lymphopenia and moderate
granulocytosis early in the infection followed by a gradual recovery
to normal leukocyte values over about 7 days.
These changes are broadly similar to those described in humans
infected with seasonal or pandemic influenza viruses, for whom
moderate lymphopenia is a common finding [40–47]. In ferrets,
although the lymphopenia was moderate on most days after
infection (e.g. ,60% of pre-challenge levels on day 5), a marked
lymphopenia was present 2 days post-infection, with lymphocytes
as a whole dropping to ,20% of pre-challenge levels and CD8+ T
cells in some ferrets dropping to 5% of pre-challenge levels.
Neutrophilia is occasionally seen in human influenza infection
[48], though it is less common in the absence of pneumonia or
bacterial co-infection [47,49–51]. All infected ferrets showed
granulocytosis (CD11b+ cells; presumably mainly due to neutro-
vaccinated animals challenged with Perth/16. { indicates p,0.0001; * indicates 0.0001,p,0.05. ‘‘MvN’’, comparing mock-infected ferrets to naı̈ve
ferrets; ‘‘MvT’’, comparing mock-infected ferrets to ferrets vaccinated with TIV; ‘‘NvT’’, comparing naı̈ve ferrets to ferrets vaccinated with TIV.
doi:10.1371/journal.pone.0100926.g004
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Figure 5. Peripheral blood leukocyte subsets following infection of naı̈ve animals with Perth/16 and NY/21. Ferrets were bled on days
0–7, 9, 11, and 13 relative to the day of viral challenge, and cells were stained and analyzed by flow cytometry as described in the text. (A) Total white
blood cell counts were obtained using a Hemavet apparatus. Percentages of (B) CD3-positive cells (T cells), (C) CD8-positive cells (cytotoxic T
lymphocytes), (D) TH cells (CD3+ and CD4+), (E) CD79a-positive cells (B cells), and (F) CD11b-positive cells excluding CD11b-high/FSC-high cells
(granulocytes) were measured. For each animal the frequencies were normalized to the ferret’s values on day 0; the Y axis represents percent of
values on day 0. ‘‘Mock’’, unvaccinated mock-infected animals; ‘‘H3N2’’, unvaccinated animals challenged with Perth/16; ‘‘H1N1pdm’’, unvaccinated
animals challenged with NY/21. { indicates p,0.0001; * indicates 0.0001,p,0.05. ‘‘MvH3’’, comparing mock-infected ferrets to ferrets infected with
Influenza Vaccination Limits Lymphopenia in Infected Ferrets
PLOS ONE | www.plosone.org 10 June 2014 | Volume 9 | Issue 6 | e100926
philia) for several days post-infection. This granulocytosis was not
simply a relative increase due to the loss of lymphocytes, but was
an absolute increase in the numbers of neutrophils (Figure S1).
Monocytosis is also commonly seen in influenza infection in
humans [43,44]; while infected ferrets often appeared to show
some degree of monocytosis, the lack of specific markers for
monocytes in these experiments and the variable levels seen in
mock-infected animals made this difficult to interpret.
As shown in previous studies [38,39], H1N1pdm09 caused a
more severe infection than did H3N2. Infection with H1N1pdm09
led to more rapid weight loss and earlier onset of fever than did
infection with H3N2, and 3- to 7-fold higher titers of H1N1pdm09
virus were shed in nasal washes (Figure 3). PBL subsets, too,
showed evidence of more severe inflammation in H1N1pdm09,
with an earlier onset of changes (day 1 vs. day 2) and a more
gradual recovery to baseline levels. H1N1pdm09 infections are
associated with extensive cytokine production [32–34] as well as
with greater replication in the lower respiratory tract than H3N2
infection [39], and all these factors are probably responsible for the
greater impact on PBL subsets. The molecular mechanisms
causing the changes in leukocyte numbers are not clear. Since we
only examined peripheral blood, migration into the respiratory
tract [39] or lymphoid tissue is likely to account for at least part of
the loss of lymphocytes. However, the kinetics of the previously
described increase in alveolar mononuclear cells in H3N2 or
H1N1pdm09 infection are apparently transient [39], which does
not correlate well with all of the changes in PBL observed here.
While migration to the respiratory tract may be responsible for the
initial loss of peripheral lymphocytes at day 2, it seems less likely
that the more prolonged reduction (to day 7) is caused solely by
migration. Alternatively, cytokines such as interferon may sensitize
lymphocytes to apoptosis [52–54] and have been associated with
lymphopenia and neutrophilia [55]. Studies of cytokine expression
in ferret lungs following influenza virus infection showed a spike in
expression of both Type I and Type II IFNs, as well as TNFa, on
day 2, followed by a return to lower levels [56,57], which
correlates with the timing of lymphocyte disappearance and
recovery observed in the present study. Further analysis of
leukocyte subsets in tissues will be required to better understand
the kinetics of PBL changes.
For the relatively mild H3N2 virus infection, there was little
clinical evidence of protection by vaccination, although most
ferrets achieved a serum antibody HI titer of 40, which in humans
is correlated with a 50% reduction in risk of influenza infection
[31,58]. Vaccinated and non-vaccinated animals lost similar
amounts of weight, but vaccinated ferrets had a slightly shorter
duration of fever and lower temperatures on several days post-
infection. These results are consistent with previous observations in
ferrets vaccinated with TIV [28].
In contrast, vaccinated ferrets did show significant differences in
several leukocyte parameters compared to naı̈ve animals, espe-
cially after 3 days post-challenge. In particular, in vaccinated
animals T cells returned to normal levels by 4 days post-infection,
and by 9 days post infection were actually slightly higher than
baseline values, whereas non-vaccinated animals showed reduced
T cell numbers through day 6 (Figure 4B–D). Similarly,
granulocytosis was relatively mild and transient (day 2 only) for
vaccinated animals, while naı̈ve animals showed a marked and
persistent granulocytosis from days 2 through 6 (Figure 4F). Some
of the difference might reflect lower viral titers in vaccinated vs
naı̈ve animals, but on day 4– when PBL counts in vaccinated
animals had returned essentially to normal – vaccinated animals
were still shedding significant levels of virus, higher than the levels
in naı̈ve animals on day 6 (Figure 3C), when the latter still showed
altered PBL levels. Possibly vaccination restricts the sites of viral
replication, allowing some viral shedding while reducing systemic
inflammation.
One common but poorly-understood outcome of influenza virus
infection is secondary infection with bacteria, such as Streptococcus
pneumoniae or S. pyogenes [5–7], that rarely cause serious infections
alone. Vaccination against influenza also confers protection
against secondary bacterial infections in animal models [6,59,60]
and humans [61]. It is interesting to speculate that the leukocyte
changes observed, especially the lymphopenia, could play a direct
role in susceptibility to bacterial infection. In any case, these
findings suggest that influenza vaccination may confer benefits
beyond the initial clinical disease, by allowing more rapid recovery
of leukocyte populations and thereby providing enhanced resis-
tance against other pathogens in the post-infection period.
Supporting Information
Figure S1 Absolute counts of peripheral blood leukocyte
subsets following infection with Perth/16. Ferrets were
bled on days 0–7, 9, 11, and 13 relative to the day of viral
challenge, and cells were stained and analyzed by flow cytometry
as described in the text. Frequencies of each subset as a percentage
of total WBC, obtained by flow cytometry, were applied to total
WBC counts as determined using the Hemavet apparatus. (A)
Total white blood cells, (B) CD3-positive cells (T cells), (C) CD8-
positive cells (cytotoxic T lymphocytes), (D) CD79a-positive cells
(B cells), (E) CD11b-high, FSC-high cells (monocytes/dendritic
cells), and (F) CD11b-positive cells excluding CD11b-high/FSC-
high cells (granulocytes) were measured. The Y axis represents
thousands of cells per ml blood. ‘‘Mock’’, unvaccinated mock-
infected animals; ‘‘Naı̈ve’’, unvaccinated animals challenged with
Perth/16; ‘‘TIV’’, vaccinated animals challenged with Perth/16. {
indicates p,0.0001; * indicates 0.0001,p,0.05. ‘‘MvN’’, com-
paring mock-infected ferrets to naı̈ve ferrets; ‘‘MvT’’, comparing
mock-infected ferrets to ferrets vaccinated with TIV; ‘‘NvT’’,
comparing naı̈ve ferrets to ferrets vaccinated with TIV.
(TIF)
Figure S2 Peripheral leukocyte changes in individual
ferrets following infection with A/Perth/16/2009.
Changes in leucocyte subsets after Perth/16 challenge for 15
naı̈ve ferrets (red traces) and 9 vaccinated animals (blue traces).
(A), CD3+ cells (T cells); (B), CD8+ve cells (cytotoxic T
lymphocytes); (C), CD11b+ve cells excluding CD11b-high/FSC-
high cells (granulocytes). Data are pooled from three independent
experiments. The Y axis represents the fraction of total WBC,
normalized to the ferret’s value on day 0.
(TIF)
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